Examination of the role of endopeptidase 3.4.24.15 in Aβ secretion by human transfected cells

British Journal of Pharmacology

Volumn 121, Issue 3, 1997, Pages 556-562

  Chevallier, Nathalie ^d   Jiracek, Jirì ^a   Vincent, Bruno ^d   Baur, Claus Peter ^b   Spillantini, Maria Gracia ^b   Goedert, Michel ^b   Dive, Vincent ^c   Checler, Frédéric ^d  

^a INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^c DIF   (France)

^d CNRS   (France)

Author keywords

secretase; A secretion; Alzheimer's disease; Endopeptidase 3.4.24.15; HK293 cells; Peptidase; Transfection

Indexed keywords

AMYLOID BETA PROTEIN; ENZYME INHIBITOR; MUTANT PROTEIN; PHOSPHINIC ACID DERIVATIVE; THIMET OLIGOPEPTIDASE;

ARTICLE; CELL LABELING; CELL LINE; CONTROLLED STUDY; DNA TRANSFECTION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN SECRETION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CELLS, CULTURED; HUMANS; METALLOENDOPEPTIDASES; RATS; TRANSFECTION;

EID: 0031001110     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701151     Document Type: Article

References (42)

1. BARELLI, H., VINCENT, J.P. & CHECLER, F. (1991). Rat brain endopeptidase 24-15: specificity towards opioids, tachykinins and neurotensin-related peptides. Comparison with the neurotensin degrading metallopeptidase endopeptidase 24-16. Neurochem. Life Sci. Advances, 10, 115-124.
2. BISSETTE, G. & MYERS, B. (1992). Somatostatin in Alzheimer's disease and depression. Life Sci., 51, 1389-1410.
3. BROWN, A.M., TUMMOLO, D.M., SPRUYT, M.A., JACOBSEN, J.S. & SONNENBERG-REINES, J. (1996). Evaluation of cathepsins D and G and EC 3.4.24.15 as candidate β-secretase proteases using peptide and amyloid precursor protein substrates. J. Neurochem., 66, 2436-2445.
4. CAI, X.-D., GOLDE, T.E. & YOUNKIN, S.G. (1993). Release of excess amyloid β protein from a natural amyloid β protein precursor. Science, 259, 514-516.
5. CHECLER, F. (1993). Neuropeptide-degrading peptidases. In Methods in Neurotransmitters and Neuropeptides Research, Part 2. ed. Nagatsu, T., Parvez, H., Naoi, M. & Parvez, S. pp. 375-418. Amsterdam: Elsevier Science Publishers.
6. CHECLER, F. (1995). Processing of the β-amyloid precursor protein and its regulation in Alzheimer's disease. J. Neurochem., 65, 1431-1444.
7. CHECLER, F., DAUCH, P., BARELLI, H., DIVE, V., MASUO, Y., VINCENT, B. & VINCENT, J.P. (1995). Identification and distribution of endopeptidase 24.16 in central nervous system. In Methods in Neuroscience, Vol. 23 ed. Smith, AI. pp. 363-382. Amsterdam: Academic Press Inc.
8. CHEVALLIER, N., MARAMBAUD, P., VIZZAVONA, J., BAUR, C.P., SPILLANTINI, M., FULCRAND, P., MARTINEZ, J., GOEDERT, M., VINCENT, J.P. & CHECLER, F. (1977). Cathepsin D displays in vitro β-secretase-like specificity. Brain Res., 750, 11-19.
9. CHU, T. & ORLOWSKI, M. (1985). Soluble metalloendopeptidase from rat brain: action on enkephalin- containing peptides and other bioactive peptides. Endocrinology, 116, 1418-1425.
10. CITRON, M., OLTERSDORF, T., HAASS, C., MCCONLOGUE, L., HUNG, A.Y., SEUBERT, P., VIGO-PELFREY, C., LIEBERBURG, I. & SELKOE, D.J. (1992). Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production. Nature, 360, 672-674.
11. CONN, K.J., PIETROPAOLO, M., JU, S.T. & ABRAHAM, C.R. (1996). Monoclonal antibodies against the human metalloprotease EC 3.4.24.15 label neurofibrillary tangles in Alzheimer's disease brain. J. Neurochem., 66, 2011-2018.
12. CORDER, E.H., SAUNDERS, A.M., STRITTMATTER, W.J., SCHMECHEL, D.E., CASKELL, P.C., SMALL, G.W., ROSES, A.D., HAINES, J.L. & PERICAK-VANCE, M.A. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 261, 921-923.
13. DAHMS, P. & MENTLEIN, R. (1992). Purification of the main somatostatin-degrading proteases from rat and pig brains, their action on other neuropeptides, and their identification as endopeptidases 24.15 and 24.16. Eur. J. Biochem., 208, 145-154.
14. FELSENSTEIN, K.M., HUNIHAN, L.W. & ROBERTS, S.B. (1994). Altered cleavage and secretion of a recombinant β-APP bearing the Swedish familial Alzheimer's disease mutation. Nature Genetics, 6, 251-256.
15. GENTLEMAN, S.M. (1992). Alzheimer's disease and βA4: getting to the core of the problem? Trends Neurosci., 15, 315-316.
16. GOEDERT, M. (1993). Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci., 16, 460-465.
17. HARDY, J. & ALLSOP, D. (1991). Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci., 12, 383-388.
18. ICHAI, C., CHEVALLIER, N., DELAERE, P., DOURNAUD, P., EPELBAUM, J., HAUW, J.J., VINCENT, J.P. & CHECLER, F. (1994). Influence of region-specific alterations of neuropeptidases content on the catabolic fates of neuropeptides in Alzheimer's disease. J. Neurochem., 62, 645-655.
19. JIRÀCEK, J., YIOTAKIS, A., VINCENT, B., CHECLER, F. & DIVE, V. (1996). Development of the first potent and selective inhibitor of the zinc endopeptidase neurolysin using a systematic approach based on combinatorial chemistry of phosphinic peptides. J. Biol. Chem., 270, 19606-19611.
20. JIRÀCEK, J., YIOTAKIS, A., VINCENT, B., LECOQ, A., NICOLAOU, A., CHECLER, F. & DIVE, V. (1995). Development of highly potent and selective phosphinic peptide inhibitors of zinc endopeptidase 24-15 using combinatorial chemistry. J. Biol. Chem., 270, 21701-21706.
21. JOACHIM, C.L. & SELKOE, D.J. (1992). The seminal role of beta-amyloid in the pathogenesis of Alzheimer disease. Alzheimer Dis. Assoc. Disorders, 6, 7-34.
22. LEW, R.A., HEY, N.J., TETAZ, T.J., GLUCKSMAN, M.J., ROBERTS, J.L. & SMITH, A.I. (1995). Substrate specificity differences between recombinant rat testes endopeptidase EC: 3.4.24.15 and the native brain enzyme. Biochem. Biophys. Res. Commun., 209, 788-795.
23. LUCIUS, R. & MENTLEIN, R. (1991). Degradation of the neuropeptide somatostatin by cultivated neuronal and glial cells. J. Biol. Chem., 266, 18907-18913.
24. MASTERS, C.L., SIMONS, G., WEINMAN, N.A., MULTHAUP, G., MCDONALD, B.L. & BEYREUTHER, K. (1985). Amyloid plaque core protein in Alzheimer's Disease and Down Syndrome. Proc. Natl. Acad. Sci. U.S.A., 82, 4245-4249.
25. MCDERMOTT, J.R., BIGGINS, J.A. & GIBSON, A.M. (1992). Human brain peptidase activity with the specificity to generate the N-terminus of the Alzheimer β-amyloid protein from its precursor. Biochem. Biophys. Res. Commun., 185, 746-752.
26. MECKELEIN, B., ROHAN DE SILVA, H.A., ROSES, A.D., RAO, P.N., PETTENATI, M.J., XU, P.T., HODGE, R., GLUCKSMAN, M.J. & ABRAHAM, C.R. (1996). Human endopeptidase (THOP1) is localized on chromosome 19 within the linkage region for the late-onset Alzheimer disease AD2 locus. Genomics, 31, 246-249.
27. MENTLEIN, R. & DAHMS, P. (1994). Endopeptidases 24.16 and 24.15 are responsible for the degradation of somatostatin, neurotensin, and other neuropeptides by cultivated rat cortical astrocytes. J. Neurochem., 62, 27-36.
28. MULLAN, M. & CRAWFORD, F. (1993). Genetic and molecular advances in Alzheimer's disease. Trends Neurosci., 16, 398-403.
29. MULLAN, M., CRAWFORD, F., AXELMAN, K., HOULDEN, H., LILIUS, L., WINBLAD, B. & LANNFELT, L. (1992). A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid. Nature Genetics, 1, 345-347.
30. NORDBERG, A. (1992). Biological markers and the cholinergic hypothesis in Alzheimer's disease. Acta Neurol. Scand., Suppl. 139, 54-58.
31. ORLOWSKI, M., MICHAUD, C. & CHU, T.G. (1983). A soluble metallopeptidase from rat brain. Purification of the enzyme and determination of specificity with synthetic and natural peptides. Eur. J. Biochem., 135, 81-88.
32. ORLOWSKI, M., MICHAUD, C. & MOLINEAUX, C.J. (1988). Substrate-related potent inhibitors of brain metalloendopeptidase. Biochemistry, 27, 597-602.
33. PAPASTOITSIS, G., SIMAN, R., SCOTT, R. & ABRAHAM, C.R. (1994). Identification of a metalloprotease from Alzheimer's disease brain able to degrade the beta-amyloid precursor protein and generate amyloidogenic fragments. Biochemistry, 33, 192-199.
34. PERRY, E.K. (1986). The cholinergic hypothesis. Ten years on. Br. Med. Bull., 42, 63-69.
35. SCHELLENBERG, G.D. (1995). Genetic dissection of Alzheimer's disease, a heterogeneous disorder. Proc. Natl. Acad. Sci. U.S.A., 92, 8552-8559.
36. SCHETTINI, G., FLORIO, T., MAGRI, G., GRIMALDI, M., MENCCI, O., LANDOLFI, E. & MANICRO, A. (1988). Somatostatin and SMS 201-995 reverse the impairment of cognitive functions induced by cysteamine depletion of brain somatostatin. Eur. J. Pharmacol., 151, 399-407.
37. SELKOE, D.J. (1991). The molecular pathology of Alzheimer's disease. Neuron, 6, 487-498.
38. TANZI, R.E., ST. GEORGE-HYSLOP, P. & GUSELLA, J.F. (1991). Molecular genetics of Alzheimer disease amyloid. J. Biol. Chem., 266, 20579-20582.
39. TISLJAR, U., KNIGHT, C.G. & BARRETT, A.J. (1990). An alternative quenched fluorimetric substrate for Pz-peptidase. Anal. Biochem., 186, 112-115.
40. VECSEI, L., BOLLOK, I. & TELEGDY, G. (1984). Phenoxybenzamine antagonizes somatostatin-induced anti-amnesia in rats. Eur. J. Pharmacol., 99, 325-328.
41. VECSEI, L. & WIDERLÖV, E. (1988). Brain and CSF somatostatin concentrations in patients with psychiatric or neurological illness. Acta Psychiatr. Scand., 78, 657-667.
42. YANKNER, B.A. & MESULAM, M.M. (1992). Beta-amyloid and the pathogenesis of Alzheimer's disease. In New Engl. J. Med., ed. Flier, J.S. & Underhill, L.H. pp. 1849-1857. Boston: Seminars in Medicine of the Beth Israël Hospital.